X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Now Rated "Moderate Buy" by Wall Street Analysts

Key Points

• Analyst sentiment is moderately positive: Six analysts rate X4 Pharmaceuticals a consensus “Moderate Buy,” with four buys, one hold and one sell. The average 12-month price target is $11.25 versus the stock’s reported $3.35 price.
• Insiders have recently reduced holdings: Company executives sold 83,779 shares worth approximately $353,000 during the last quarter, while insiders collectively own 1.13% of the stock. Institutional investors own a much larger 72.03% stake.
• X4 remains an unprofitable biotech but exceeded quarterly expectations: The company reported a quarterly loss of $0.13 per share, beating estimates, and revenue of $8.81 million versus a $2.42 million consensus forecast. Its lead product, XOLREMDI, is FDA-approved for patients aged 12 and older with WHIM syndrome.

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $11.25.

A number of research analysts have commented on XFOR shares. Wells Fargo & Company started coverage on shares of X4 Pharmaceuticals in a research note on Friday, July 10th. They issued an "overweight" rating and a $11.00 price objective on the stock. Weiss Ratings cut shares of X4 Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, October 20th.

Insiders Place Their Bets

In other X4 Pharmaceuticals news, President John Volpone sold 24,576 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $109,117.44. Following the completion of the transaction, the president directly owned 265,305 shares in the company, valued at $1,177,954.20. This trade represents a 8.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman Adam Craig sold 47,436 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total value of $210,615.84. Following the completion of the sale, the chairman owned 328,651 shares of the company's stock, valued at $1,459,210.44. The trade was a 12.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 83,779 shares of company stock worth $353,387. Insiders own 1.13% of the company's stock.

Institutional Trading of X4 Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. WINTON GROUP Ltd increased its stake in shares of X4 Pharmaceuticals by 35.8% during the second quarter. WINTON GROUP Ltd now owns 14,400 shares of the company's stock worth $67,000 after purchasing an additional 3,800 shares in the last quarter. Pettinga Financial Advisors LLC purchased a new stake in shares of X4 Pharmaceuticals in the second quarter valued at about $47,000. SummitTX Capital L.P. purchased a new position in shares of X4 Pharmaceuticals during the 1st quarter worth approximately $46,000. AXQ Capital LP acquired a new position in X4 Pharmaceuticals during the second quarter worth $107,000. Finally, Wellington Management Group LLP acquired a new stake in shares of X4 Pharmaceuticals during the 2nd quarter worth about $242,000. 72.03% of the stock is currently owned by institutional investors.

X4 Pharmaceuticals Stock Performance

Shares of XFOR stock opened at $3.35 on Monday. X4 Pharmaceuticals has a 12-month low of $2.43 and a 12-month high of $4.83. The company has a current ratio of 11.30, a quick ratio of 11.02 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $332.15 million, a price-to-earnings ratio of -2.79 and a beta of 0.47. The stock's 50-day moving average price is $3.33 and its 200-day moving average price is $3.80.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.05. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%. The firm had revenue of $8.81 million during the quarter, compared to analyst estimates of $2.42 million. Equities research analysts predict that X4 Pharmaceuticals will post -0.67 EPS for the current fiscal year.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company's research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4's lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.